Finance & Capital Markets

  1. The Legend Steve Gorlin's Golden Rules 11/1/2023

    Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

  2. The Biotech Beatdown With Allan Shaw 6/6/2022

    On this, the 100th episode of the Business of Biotech podcast, our dear friend, frequent guest, and business of biotech brainiac Allan Shaw joins us to dissect the beleaguered biotech capital markets. We pick apart what's driving sentiment and how we got here, whether the industry is over-inventoried, what's getting funded , what's not, and why, and what biotech leaders should be doing in an investment landscape marked by hyper-discernment. We also reflect on the podcast journey and celebrate the 100-episode milestone!

  3. Biotech Angel Investing With Yaniv Sneor 5/21/2025

    On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. The conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.

  4. A Look Behind, A Look Ahead With Allan Shaw 1/4/2021

    The Business Of Biotech kicks off the new year with an up-close-and-personal talk with biotech investor and CFO extraordinaire Allan Shaw. We talk through last year's ups and downs and do a little prognosticating on what we're feeling bullish about--from unprecedented regulatory action to exciting progress on the cell and gene front--as we head into the new year.

  5. Biotech Capital Markets Forecast With Allan Shaw 1/23/2022

    As Allan Shaw likes to say, "there have never been so many people with their hands out, and there has never been so much money to go around." But how sustainable is this seemingly perennial boom in the biotech capital markets? Will the road go on forever and the party never end, or are there signs of a slowdown on the horizon? Shaw once again joins us to break down the market activity he's seeing, and what he anticipates for early-stage biotech leaders in 2022. 

  6. Veteran Advice From The C-Suite With Citius' Leonard Mazur 10/4/2023

    Leonard Mazur has been in the business of biotech for a long, long time, and he has no intention of stopping now. He’s faced challenges won, lost, and ongoing, and he’s willing to share his experiences—from winning FDA approvals to bootstrapping his current effort at Citius Pharmaceuticals—with the transparent confidence of an industry veteran.

  7. Biotech Is Back With Allan Shaw 1/24/2024

    The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and we're kicking things off with everyone's favorite life sciences CFO, Allan Shaw.